Reata Pharmaceuticals Sees Unusually Large Options Volume
About 67% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Reata |
Reata Pharmaceuticals, Inc. was the target of some unusual options trading on Friday. Stock investors bought 5,018 put options on the stock. This represents an increase of 180 percent compared to the average volume of 1,794 put options. Analyst Ratings Changes RETA has been the topic of several research analyst reports.
Read at thelincolnianonline.com
 |
Reata Pharmaceuticals Fundamental Analysis
We analyze Reata Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Reata Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Reata Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reata Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Reata Pharmaceuticals Related Equities
| PPCB | Propanc Biopharma | 17.39 | ||||
| PTCT | PTC Therapeutics | 9.27 | ||||
| SRPT | Sarepta Therapeutics | 3.58 | ||||
| VIR | Vir Biotechnology | 3.45 | ||||
| KRYS | Krystal Biotech | 3.40 | ||||
| AKRO | Akero Therapeutics | 2.87 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.65 | ||||
| CVAC | CureVac NV | 1.31 | ||||
| VKTX | Viking Therapeutics | 0.70 | ||||
| TERN | Terns Pharmaceuticals | 1.86 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |